Simon Witty

Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $2.5 billion initial public offering of 89,333,920 of its Class A ordinary shares, which included an…

Davis Polk advised the joint lead managers in connection with a Rule 144A/Regulation S offering by the Emirate of Abu Dhabi of $1 billion aggregate principal amount of 2.500% notes due…

Davis Polk advised the joint lead managers in connection with a Rule 144A/Regulation S offering by the Emirate of Abu Dhabi of $2 billion aggregate principal amount of 2.500% notes due 2025…

Davis Polk is advising Tencent Holdings Limited in connection with its acquisition of a 9.96% shareholding in Sumo Group plc. The shares are being acquired from Sumo Group’s largest…

Davis Polk advised Oryzon Genomics, S.A. on its €20 million private placement of its ordinary shares pursuant to a capital increase. The offering consisted of a private placement to…

Davis Polk advised the initial purchasers in connection with a $200 million senior perpetual capital securities offering by Zhenro Properties Group Limited. Zhenro Properties Group Limited…

Davis Polk advised the joint active bookrunners and representatives of the several initial purchasers in connection with a Rule 144A/Regulation S offering of notes by Gold Fields Orogen…

Davis Polk is advising Mereo BioPharma Group plc on its combination with OncoMed Pharmaceuticals, Inc. The transaction, which is subject to customary closing conditions and the approval of…

Davis Polk advised Laboratorios Farmacéuticos Rovi, S.A. on its Rule 144A/Regulation S follow-on offering of 5,517,241 of its ordinary shares to raise gross proceeds of approximately €80…

Davis Polk advised the dealer managers in connection with a liability management exercise by Novo Banco, S.A. with respect to 20 series of its outstanding senior debt securities, offering…